ERBB2 and breast cancer: The second subtype relies on over-production of the receptor tyrosine kinase (RTK) HER2 and resulting over-activation of the RTK pathway for excessive cell proliferation; the targeted treatment with anti-HER2 monoclonal antibodies, marketed under the trastuzumab (Herceptin) trade names, is typically applied against this BC subtype10.